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ABSTRACT 
 
PENILAIAN FAKTOR – FAKTOR PROGNOSIS PESAKIT – PESAKIT 
OSTEOSARCOMA: PENGALAMAN HUSM 
 
Dr Azlan Mohd Sofian 
MMed Ortho 
 
Jabatan Orthopedik 
Pusat Pengajian Sains Kesihatan, Universiti Sains Malaysia, 
Kampus Kesihatan, 16150 
Kelantan, Malaysia. 
 
Pengenalan: 
 Osteosarcoma adalah kanser tulang yang amat merbahaya, maka 
penilaian faktor-faktor prognosis yang akan mempengaruhi kadar kemandirian 
adalah amat penting untuk menentukan pendekatan rawatan yang optimum 
terhadap pesakit-pesakit ini. Walaupun dengan kemajuan dan pengkhususan 
di dalam bidang kemoterapi, masih terdapat di antara 30 – 40% pesakit 
meninggal dunia disebabkan oleh osteosarcoma; oleh itu faktor-faktor 
prognosis yang boleh dipercayai adalah mustahak untuk merancang rangka 
perawatan yang lebih agresif kepada pesakit – pesakit yang menpunyai risiko 
tinggi untuk kegagalan rawatan. Di antara beberapa pembolehubah yang 
telah dikenalpasti, metastasis paru – paru dan kemo-nekrosis adalah 
komponen prognosis yang terbaik untuk mengenalpasti kelangsungan hidup. 
Pada ketika ini, tidak ada kata sepakat tentang kepentingan prognosis 
penanda biokimia iaitu serum pra-rawatan alkaline phosphatase (ALP) dan 
lactate dehydrogenase (LDH). Kajian ini menganalisis faktor – faktor 
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prognosis untuk osteosarcoma, secara khususnya ALP dan LDH, dan juga 
hasil kemandirian secara kesuluruhan. 
 
Kaedah: 
 Data klinikal sekurang-kurangnya 5 tahun yang berkaitan dengan 
faktor-faktor prognosis daripada 163 pesakit osteosarcoma yang berada di 
bawah rawatn susulan Hospital Universiti Sains Malaysia telah dikaji semula 
secara retrospektif. Ini adalah satu kajian kohort retrospektif daripada semua 
pesakit yang dirawat di antara Januari 2005 dan Disember 2010. Sejumlah 
163 pesakit, dengan usia purata sebanyak 18.9 tahun (julat 6 - 59 tahun) 
telah dinilai. Terdapat 109 lelaki dan 54 perempuan. Sebahagian besar 
pesakit adalah daripada latar belakang etnik Melayu (82.2%), berbanding 
dengan kaum Cina (11.66%), diikuti oleh kaum India (4.29%). 55.2% daripada 
pesakit kami mempunyai metastasis paru-paru. Dari segi jenis pembedahan, 
66.1% daripada pesakit menjalani pembedahan limb salvage surgery (LSS) 
dan 33.9% telah menjalani amputasi. 
 
Keputusan: 
 Kadar survival keseluruhan adalah 40.5%. Purata serum pra-rawatan 
LDH adalah 493,19 IU/L, dan 52.8 % daripada pesakit kami mempunyai nilai 
yang tinggi. Purata serum pra-rawatan ALP adalah 273,93 IU/L, dan 53% 
daripada pesakit kami mempunyai nilai yang tinggi. Kadar survival secara 
keseluruhan 5 tahun untuk pesakit di dalam kumpulan serum pra-rawatan 
LDH normal adalah 66.2%, manakala di dalam kumpulan serum pra-rawatan 
LDH yang tinggi kadarnya adalah 17.4%. 
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 Kadar survival secara keseluruhan 5 tahun bagi pesakit di dalam 
kumpulan serum pra-rawatan ALP normal adalah 55.8%, manakala di dalam 
kumpulan serum pra-rawatan yang tinggi ALP kadarnya adalah 26.7%. Di 
dalam analisis statistik multivariat, hanya serum pra-rawatan LDH dan 
kehadiran metastasis mengekalkan kepentingan prognosis, manakala kedua-
dua serum pra-rawatan ALP dan jenis pembedahan hilang nilai 
pembolehubah tidak bersandar. Berkenaan pembolehubah yang lain, 66.9% 
daripada pesakit adalah lelaki, dengan kadar survival 39.4%. Pesakit wanita 
kami juga mempunyai kadar survival yang serupa iaitu 42.6%. Metastasis 
paru-paru wujud di dalam 90 pesakit (55.2%) kami. Kadar survival 
keseluruhan pesakit-pesakit ini adalah 27.8% berbanding dengan 56.2% pada 
mereka yang tidak mempunyai penyakit metastatik. Bagi pesakit yang 
menjalani pembedahan LSS, kadar survival adalah 56.8%, manakala di 
dalam kumpulan amputasi kadar survival keseluruhan adalah 17.6%. 
 
Kesimpulan: 
 Kadar survival keseluruhan pesakit osteosarcoma kami dipengaruhi 
oleh kehadiran metastasis paru-paru dan jenis pembedahan. Serum pra-
rawatan LDH dan ALP juga mempengaruhi kadar survival mereka. 
Walaubagaimanapun, umur, jantina, bangsa, tumor utama, jenis histologi, 
tidak mempengaruhi kadar survival pesakit – pesakit osteosarcoma kami. 
 
 
Supervisor: Professor Wan Faisham Nu’man Wan Ismail 
 
Evaluation of Prognostic Factors in Patients with Osteosarcoma: The HUSM Experience 
 
 
 
 
 
vii 
ABSTRACT 
 
EVALUATION OF PROGNOSTIC FACTORS IN PATIENTS WITH 
OSTEOSARCOMA: THE HUSM EXPERIENCE 
 
Dr Azlan Mohd Sofian 
MMed Ortho 
 
Department of Orthopaedics 
School of Medical Sciences, Universiti Sains Malaysia, 
Health Campus, 16150 
Kelantan, Malaysia. 
 
Introduction: 
 Osteosarcoma is a highly malignant primary bone tumour thus the 
evaluation of prognostic factors influencing the survival rates is extremely 
essential for defining the approach to the management of these patients. 
Despite the recent advancement in chemotherapy and improved prognosis, 
30 - 40% of patients still succumb to the disease; therefore reliable prognostic 
factors would be essential to plan a more aggressive treatment in patients at a 
higher risk of failure of treatment. 
 
 Among multiple variables evaluated in literatures, it is known that 
pulmonary metastases and chemo-necrosis are the best prognostic 
components on the survival. At present, there is no consensus on the 
prognostic significance of simple and cheap biochemical markers of pre-
treatment serum alkaline phosphate (ALP) and lactate dehydrogenase (LDH). 
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This study analyzed the prognostic factors of particularly ALP and LDH and 
other general variable for prognosis and overall oncological outcome. 
 
Method: 
 Clinical data of at least 5 years related to prognostic factors of 163 
patients with osteosarcoma who were under follow-up under Hospital 
Universiti Sains Malaysia were retrospectively reviewed. This was a 
retrospective cohort study of all patients treated between January 2005 and 
December 2010. A total of 163 patients with the mean age of 18.9 years 
(range 6 – 59 years old) were evaluated. There were 109 males and 54 
females. Majority of the patients were of Malay ethnic background (82.2%), 
compared to the Chinese (11.66%), followed by Indian ethnicity (4.29%). 
55.2% of our patients presented with pulmonary metastases. In terms of type 
of surgery, 66.1% of our patients underwent limb salvage surgery and 33.9% 
underwent amputation. 
 
Results: 
 The overall survival was 40.5%. The mean pre-treatment serum LDH 
level was 493.19 IU/L, and 52.8% of our patients had high values. The mean 
level of pre-treatment ALP was 273.93 IU/L, and 53% of our patients had high 
values. The 5-year overall survival rate of patients in the normal pre-treatment 
serum LDH group is 66.2%, whereas in the high pre-treatment serum LDH 
group is 17.4%.  
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 The 5-year overall survival rate of patients in the normal pre-treatment 
serum ALP group is 55.8 %, whereas in the high pre-treatment serum ALP 
group is 26.7%. In the multivariate statistical analysis, only the pre-treatment 
serum LDH and presence of metastasis maintained its prognostic significance 
as both the pre-treatment serum ALP and the type of surgery loses its 
independent predictive value. 
 
 In regards to the other variables, 66.9% of our patients were male, with 
the overall survival of 39.4%. Our female patients had a similar overall 
survival of 42.6%. Pulmonary metastases presented in 90 patients (55.2%). 
The overall survival of these patients was 27.8% compared to 56.2% in those 
without metastatic disease. For patients who underwent limb-sparing surgery, 
their overall survival was 56.8%, whereas in the amputation group the overall 
survival was 17.6%. 
 
Conclusion: 
 The overall survival of our osteosarcoma patients was influenced by 
the presence of pulmonary metastases and type of surgery. Pre-treatment 
serum LDH and ALP were of significant influence on the final survival. 
However age, gender, race, primary site of tumour, histological sub-type, 
were not of significant influence on the survival of our patients. 
 
 
Supervisor: Professor Wan Faisham Nu’man Wan Ismail 
Evaluation of Prognostic Factors in Patients with Osteosarcoma: The HUSM Experience 
 
 
1	  	  
 
 
 
 
 
 
CHAPTER1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation of Prognostic Factors in Patients with Osteosarcoma: The HUSM Experience 
 
 
2	  	  
 
INTRODUCTION 
 
1.1  Problem Statement 
 Osteosarcoma is a primary malignant tumour derived from primitive 
bone forming mesenchymal tissue, which is characterized by production of 
osteoid or immature bone, by malignant proliferating spindle cells. It most 
commonly affects the adolescent and childhood age group, and has a strong 
predilection for around the knee region.   
 Treatment typically includes preoperative chemotherapy, surgical 
resection, and postoperative chemotherapy. Limb-salvage procedures with 
wide surgical margins are the mainstay of surgical intervention. Advances in 
chemotherapy protocols have led to a 5-year survival rate of 60% to 70%. 
Despite improved prognosis recently, roughly about 30-40% of patients still 
succumb to the disease; therefore reliable prognostic factors would be 
essential to plan a more aggressive treatment in patients at a higher risk of 
relapse. 
Although it is widely reported in Western countries, but in Asian 
population where the incidence is not well documented, those reported 
prognostic factors may not have the same influence on clinical outcome. 
Furthermore, as we are among the few referral centres around this region of 
South East Asia for musculoskeletal tumour, there is a need to establish a 
database and to review the outcome of the patients treated here in Hospital 
Universiti Sains Malaysia.  
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1.2 Justification of the Study 
 This study was designed because at the current moment there is no 
similar study done in our population as reference. Although the disease is 
widely reported in Western and European population, but in the Asian 
community with it is not well documented. 
 
1.3  Benefit of the Study 
 What we aim from this study is to identify the possible prognostic 
factors in relation to our osteosarcoma patients, as there is a need to 
distinguish patients with high risk of having disease relapse or risk of 
developing metastases which may indicate chemo-resistant patients. Thus, a 
better or intensified treatment could be prescribed to avoid recurrence and 
improved survivorship, and also preventing from over-treating a patient. This 
may trigger a future scoring system in evaluating prognosis of the patients 
which may help as a guideline in delivering optimum treatment. And we hope 
to create a systematic method of data collection among our patients, as well 
as collaboration with other musculo-oncology centres here in Malaysia. 
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LITERATURE REVIEW 
 
2.1  Diagnosis 
Biopsy is a crucial step in the management of musculoskeletal 
sarcoma (Mohana, Faisham et al., 2007). The diagnosis of osteosarcoma 
requires tissue biopsy to provide histopathological examination of the lesion, 
in correlation with the clinical and also radiological findings of the patient. The 
biopsy site must be selected or planned with consideration for definitive 
tumour resection. The subsequent surgical approach for the tumour resection 
must include the biopsy tract along, as it must be removed en bloc with the 
tumour mass, as to reduce the risk of local recurrence. Biopsies that are done 
badly or against the principles of biopsy, poorly placed incisions and ensuing 
complications of biopsy procedure can considerably compromise subsequent 
management of the tumour. It is advisable that the biopsy be performed by 
the same surgeon, who will also likely perform the subsequent tumour surgery 
on the patient (Simon, 1982; Simon & Bierman, 1993). 
 
The tissue diagnosis is essential before an oncologist can decide on a 
treatment plan for musculoskeletal tumours. It also has prognostic 
implications as well as therapeutic consequences. It is universally accepted 
that the resection of the entire biopsy tract is mandatory for surgical treatment 
of osteosarcoma (Mohana, Faisham et al., 2007). 
 
The biopsy can be either with an open method, or incisional biopsy; or 
with a closed method or needle biopsy. Furthermore, the needle biopsy can 
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be a core biopsy or a fine needle core biopsy (trephine). In an established and 
experienced musculoskeletal oncology centres, needle biopsies can yield high 
positive results (Stoker et. al., 1991) 
 
Characteristic elongated cells called spindle tumour cells (centre of 
image, with purple nuclei) some of which are very abnormal (arrow) have 
replaced the normal bone marrow, and deposited new, but disorganized bone 
tissue (pink areas/asterisk).  
 
This abnormal bone deposition of cells is the hallmark of an 
osteosarcoma. 
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2.2  Incidence  
 Osteosarcoma is the most commonly diagnosed primary non-
hematopoietic malignancy of the bone, particularly among children and 
adolescents. Osteosarcoma incidence in childhood and adolescence seems 
to be relatively consistent throughout the world (Mirabello et al., 2009). 
  
In Western literature, it is reported that the disease affects 
approximately 560 children and adolescents each year in the United States 
(Horner et al., 2009). Osteosarcoma incidence in the youngest cases (age 0–
24 years) was greatest in Asian or Pacific Islanders, whereas it was greatest 
in Blacks and Whites in the middle age group (age 25–59 years) and elderly 
(age 60+ years) patients, respectively (Mirabello et al., 2009). 
 
The incidence of osteosarcoma in Malaysia, among the three separate 
major racial groups was reported to be between 0.11 (Malays) to 0.23 
(Chinese and Indians) per 100000 population, per year (Silva et al., 1974). 
  
According to Mirabello in 2009, using the Cancer Incidence in Five 
Continents, International Agency for Cancer Research database, they found 
out that osteosarcoma incidence rates among individuals who were less than 
24 years were generally consistent worldwide, with peaks around time of 
puberty. Most incidence rates ranged from 3 to 5 per million in men (average 
4.3) and 2 to 4 per million in women (average 3.4). The disease was more 
common in men than women in most countries. The overall world male-to-
female ratio of osteosarcoma in ages 0 to 24 years was 1.43:1. The incidence 
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peaked in men at the age 15 to 19 years, while in women they peaked at 10 
to 14 years of age. Osteosarcoma was more common in men than in women 
in most countries, with a male-to-female ratio of 1.28:1. 
 
2.3  Prognosis 
 Prior to the introduction of chemotherapy, when amputation was the 
mainstay of treatment for patients with osteosarcoma, the predicted long-term 
survival rate was about 10% to 20% (Dahlin et. al.,1967; Gaffney et al., 2006; 
Longhi et al., 2005). 
 
 These miserable survival rates were presumably attributable to 
pulmonary metastatic disease. Since then survival rates dramatically 
increased during the 1970s and 1980s with the evolution of chemotherapy. In 
one study, adjuvant therapy, in conjunction with surgical resection, resulted in 
improved long-term survival rates of 60% to 65% (Link et al., 1986). 
 
Based on western literatures, at the moment the long-term survival 
rates are about 60% to 78% for patients with localized osteosarcoma (Bacci et 
al., 2000; Bielack et al., 2002). 
 
Despite the use of chemotherapy, the expected 10-year survival rate 
declines significantly to 20% to 30% in patients with clinically detectable 
metastasis (Bielack et al., 2002; Kager et al., 2003). Most of the patients that 
do not survive ultimately die because of respiratory failure caused by the 
metastatic complications (Meyers & Gorlick, 1997). 
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Poor prognostic factors for patients with osteosarcoma include 
metastasis on presentation, primary tumour located in the axial skeleton, large 
tumour volume, increased alkaline phosphatase or lactate dehydrogenase 
levels, poor response to preoperative chemotherapy, discontinuous tumour of 
bone, and any presence of lymph node involvement (Bielack et al., 2002; 
Kager et al., 2003; Meyers & Gorlick, 1997). 
 
2.4  Treatment 
A multidisciplinary approach is needed in the treatment of patients with 
osteosarcoma, including surgical and oncologic specialists. 
 
As mentioned before, prior to 1970s, amputation was the only surgical 
treatment available for osteosarcoma, and 80% of patients died of metastatic 
disease, mainly involving the lungs. 
 
Thus currently it universally accepted that the treatment strategy of 
managing osteosarcoma patients, is giving preoperative chemotherapy, or 
neo-adjuvant chemotherapy, followed by surgery and adjuvant therapy. This 
approach has greatly improved the survival rates of patients with the disease. 
 
In our clinical setting, the chemotherapy regime that was used to treat 
paediatric patients in follows the Memorial Sloan Kettering T10 protocol (Cho 
et al., 2011; Rosen et al., 1982), albeit with some modifications. 
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The total duration for this regime is about 12 months. This includes 3 
phases. Phase One is given to the patients pre-operatively, which consists of 
Vincristine at week 1, then high dose Methotrexate at week 2 and 3, which is 
followed by Vincristine after each dose of the above-mentioned Methotrexate. 
After that at week 4, Vincristine is given again.  
 
At week 5, surgical resection of the tumour is done, followed by Phase 
Two of the chemotherapy regime. This includes giving Bleomycin, Cisplatin 
and Dactinomycin at week 5, subsequently after the surgery. 3 weeks after 
that, high dose Methotrexate is given at week 9 and 10, with each dose 
followed by Vincristine. At week 11, Adriamycin is given to this group of 
patients. Then after 3 weeks, which is approximately at week 14 and 15, 
another 2 high doses Methotrexate is given, and again each dose is followed 
by a dose of Vincristine. 
 
At week 20, Phase Three is commenced with maintenance 
chemotherapy which includes either the Arm T10A or the Arm T10B protocol 
at week 20. In Arm T10 A protocol, treatment is given to patients who are poor 
responders to chemotherapy. This includes giving Adriamycin and Cisplatin 
which is repeated after 2 weeks. Then after 3 weeks, Bleomycin, Cisplatin and 
Dactinomycin is given for a duration of about 6 weeks. 
 
Meanwhile in the Arm T10 B protocol, treatment is given to patients 
with good response to chemotherapy .This includes giving Bleomycin, 
Cisplatin and Dactinomycin at week 20, as previously mentioned. After 3 
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weeks, high dose Methotrexate, followed by Vincristine is given twice, at 
weekly intervals. This is followed by Adriamycin. Another 3 weeks after that, a 
further high dose of Methotrexate is given, and again followed by Vincristine, 
given twice at weekly intervals. 
 
 In adolescents or adult patients, the chemotherapy regime used in our 
hospital setup as a first line of treatment is based on the European 
Osteosarcoma Intergroup (Craft, 2009) protocol. This protocol is utilized prior 
to the limb salvage surgery, and after a thorough work up of the patient. The 
work up includes 24 hours urine creatinine clearance estimation, full blood 
counts, renal function tests and liver function tests.  
 
 After 3 cycles of chemotherapy, the patients were evaluated for the 
limb salvage surgery. The post-operative histopathological examination report 
is reviewed for the continuation and or modification of the chemotherapy. If 
the tumour necrosis factor is more than 95%, then the same pre-operative 
regime is continued post-operatively. If the necrosis is less than 95%, then the 
patient will be considered for the second line chemotherapy. In addition, the 
second line of regime is also given to patients who developed metastasis 
during the treatment period.  
 
 First line chemotherapy includes, injections of Cisplatin at 100mg/m2 
divided in 3 days is given 6 hourly each day; injections of Adriamycin at 
25mg/m2  in 24 hours infusion for 3 days, along with anti-emetic cover with H2 
receptor antagonists, to minimize the side effects of nausea and vomiting. 
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These schedule will be repeated every 3 weeks for a total of 6 cycles; 3 
cycles preoperatively, after which followed by 3 cycles after the tumour 
surgery.  
 
 As for second line of chemotherapy, injections of Ifosfamide 2gm/m2  is 
given for 2 hours infusion, for 4 days with injections of Mesna 20% of the 
Ifosfamide dose given at 0, 4 and 8 hours after the mentioned Ifosfamide 
injections, to help protect the bladder from the urotoxic metabolites of the 
Ifosfamide. Next are the injections of Etoposide at 100 mg/m2, given for an 
hour infusion for 4 days. This is repeated every 4 weeks, for a total of 4 cycles. 
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2.5  Prognostic Factors 
Biological Prognostic Factors: 
More than 2 decades ago there was a review article about prognostic 
factors in non-metastatic osteosarcoma of the extremities, which was based 
on the analysis of eight reports published between 1973 and1992, which 
concluded that the most important prognostic variable for patients with 
osteosarcoma of the extremities was the rate of tumour necrosis induced by 
pre-operative chemotherapy, however there was no consensus on the 
prognostic significance of patient gender or age and tumour size and location. 
In that same report, no mention was made of the role of biochemical markers 
such as serum alkaline phosphatase (ALP) and lactate dehydrogenase(LDH) 
(Davis et al., 1994) 
 
The available literature on the prognostic value of the alkaline 
phosphatase (ALP) and lactate dehydrogenase (LDH) serum levels remains 
controversial till today. Several authors describe a correlation of pre-treatment 
levels of the two above-mentioned serological markers within the normal 
range with a better outcome (Bacci et al., 1996); whereas there are other 
authors that could find such an association only for serum LDH, but not for 
serum ALP (Pochanugool et al., 1997). 
 
According to COSS, the interdisciplinary Cooperative German-
Austrian-Swiss Osteosarcoma Study Group, which was founded in 1977 and 
has since registered more than 3,000 osteosarcoma patients from more than 
over 200 institutions; demonstrated in their series a correlation of a high 
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serum ALP serum values with a worse outcome. Other serum factors like 
erythrocyte sedimentation rate, lymphocyte count, and serum albumin were 
found to be of no prognostic value (COSS-80, COSS-86). 
 
2.5.1 Lactate Dehydrogenase (LDH) 
The glycolytic enzyme lactate dehydrogenase (LDH)is a biological 
marker for cytosol in various tissues, and its serum levels are high in much 
pathology. In bone tumours, serum LDH has been found helpful as a 
prognostic factor and to evaluate the response to treatment in patients with 
Ewing’s sarcoma (Bacci et al., 1999). Previously, little is known about the 
significance of serum LDH levels in patients with osteosarcoma. The 
observation of LDH production by human osteosarcoma transplanted into 
nude suggested that LDH could also be a useful biological marker in this 
tumour (Nakamura & Kitagawa, 1985). Nevertheless, the possible correlation 
between serum LDH levels and prognosis has been investigated in a small 
number of clinical studies (Bacci et al; 1994; Link et al, 1993; Meyers et al., 
1993). 
 
In a paper published by the esteemed group from Rizzoli Institute, in a 
study involving 656 patients, they reported serum LDH level to have a clear 
prognostic value in patients with osteosarcoma of the extremity (Bacci et at., 
1994). They reported that pre-treatment serum LDH levels were a significantly 
important prognostic factor. Taking into consideration of patients with 
localized disease at presentation, the 5-year disease-free survival was 72% in 
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those with normal LDH values and 54% in those with high pre-treatment 
serum LDH levels.  
 
Subsequently 10 years later, a follow-up study involving a larger series 
of 1421 patients, of which their pre-treatment serum LDH were analysed, and 
they concluded that the pre-treatment serum LDH had prognostic value, and it 
should be considered in evaluating the results of therapeutic trials of 
chemotherapy, as well as defining a category of patients at high-risk of 
relapse to be treated with a more aggressive protocols (Bacci et al., 2004).  
 
In this study the activity of serum LDH was estimated by the standard 
method by the German Society of Clinical Chemistry; of which serum levels 
lower than 240 IU/L were considered normal, whereas values greater than 
240 IU/L were considered pathologically high. They observed that the 
percentage of patients with elevated pre-treatment serum LDH levels in the 
group of patients with metastatic disease was 2-fold to that of the group of 
patients with localized disease, which was statistically significant. 
 
In regards to pre-treatment serum ALP levels, they observed that pre-
treatment serum LDH was significantly higher in patients who also had 
increased levels of serum ALP, in comparison with those patients with normal 
values of the serological marker, which was also statistically significant. 
 
Another observation they made is the association of pre-treatment 
serum LDH with the stage of the disease; they reported that the specificity of 
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high pre-treatment serum LDH levels in detecting metastatic patients was high 
(0.81), but its sensitivity was low (0.38). More so, only 36% of patients with 
metastatic tumour at presentation had high pre-treatment serum LDH levels. 
Consequently due to the fact that their patients with metastatic disease 
differed for number and sites of secondary lesions, also and due to their non-
standardized treatment, the correlation between pre-treatment serum LDH 
and outcome was not evaluated. 
 
Furthermore, correlation between pre-treatment serum LDH and 
outcome in patients with localized was also evaluated, the 5-year survival rate 
was 60% for patients with normal pre-treatment serum LDH values, and 
39.5% for patients with elevated pre-treatment serum LDH levels. They 
reported that the correlation between pre-treatment serum LDH and the 
survival outcome was highly specific but with a low sensitivity. Adding to that, 
they also considered the association between pre-treatment serum LDH with 
the time of death in those patients who succumbed to the disease. The noted 
that for patients who died of the tumour, the time of death (calculated from the 
beginning of treatment), was significantly longer in patients with normal pre-
treatment serum LDH levels than those with high values. 
 
However, they reported that prognostic significance of pre-treatment 
serum LDH disappeared when the variable of histological response was 
included in the multivariate analysis, and they concluded that in spite of this 
consideration, on the basis of their study, they believed that pre-treatment 
serum LDH values should be reported in papers concerning the combined 
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treatment of this osteosarcoma. This to make comparison of the results 
achieved with different treatment protocols, in different trials or in single 
institution studies more reliable. 
 
They further added that pre-treatment serum LDH levels should also be 
considered in planning new randomized clinical trials to compare different 
protocols of chemotherapy. In recent years, risk-adapted chemotherapy 
protocols have been designed. The prognostic factors considered to stratify 
patients in these protocols were tumour size and histological subtype, in 
addition to the histological response to pre-operative treatment; and 
considering the results of their latest study, they believed that pre-treatment 
serum LDH should be considered for this purpose. 
 
In another relevant study, using the Multi-Institutional Osteosarcoma 
Study Evaluation, the authors found that an initial serum LDH greater than 
400 IU/L was the best predictor of outcome in osteosarcoma patients (Link et 
al., 1991). They reported that pre-treatment serum LDH level to be the only 
prognostic factor significant by multivariate analysis. In fact, the rate of event-
free survival at 8 years was 40% for the 31 patients with high serum levels 
and 74% for the 82 patients with normal values. 
 
Likewise, in another study of a 10-year experience of adjuvant and 
neoadjuvant chemotherapy for osteosarcoma of the extremities, involving 255 
patients, they demonstrated by multivariate analysis that the disease-free 
survival correlated with initial baseline lower pre-treatment serum LDH. The 
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cumulative probability of disease-free survival was 62.2% for patients with 
normal LDH levels and only 42% for the group of patients with high levels 
(Meyers et al., 1993). 
 
A report on evaluation of the relationship between patient-related and 
treatment-related factors and prognosis was carried out in 300 osteosarcoma 
patients treated from 1986 to 1992, showed that the pre-treatment serum LDH 
was predictive of disease-free survival, and a significantly more favourable 
prognosis was found in patients with normal values (8-year DFS of 63%), 
compared to the group of patients with high values (8-year DFS of 51%) 
(Ferrari et al., 2001) 
 
2.5.2 Alkaline Phosphatase (ALP) 
Alkaline phosphatase (ALP) is a non-specific enzyme that can 
hydrolyze variety of phosphate in alkaline hydrolysis conditions. It is a 
membrane metal glycoprotein, formed by four isozymes. Many pathological 
conditions or diseases cause different isozyme elevation, thus increasing the 
total activity of the ALP. Because the enzyme is derived from multi-source, 
ALP increase was not specifically caused by changes in bone metabolism 
(Hayashi, 2004). 
 
In comparison with the prognostic significance pre-treatment LDH, the 
prognostic importance of pre-treatment serum ALP levels has been more 
widely reported by several authors (Bacci et al., 2002; Lockshin et al., 1968; 
Meyers at al., 1993; McKenna et al., 1966; Thorpe et al., 1979).  
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Alkaline phosphatase (ALP) is an easy, cost effective method to 
evaluate, at any stage of the disease, and has been shown by some authors 
to have a predictive value for survival (Bacci et al., 1993; Ferrari et al., 2001; 
Stokkel et al., 2002; Thorpe et al., 1979) or chemotherapy response 
(Juergens et al., 1981) Others however did not find a correlation of pre-
treatment serum ALP for either survival outcome nor chemotherapy response 
(Pochanugool et al., 1997). 
 
Most authors report only on ALP levels before chemotherapy, or after 
surgery. Alkaline phosphatase (ALP) has specifically been addressed as a 
prognostic factor by several authors. The enzyme has been shown to be 
produced directly by osteosarcoma cells and its level can be raised in patients 
with osteosarcoma (Singh et al., 1974). 
 
Before the era of neo-adjuvant chemotherapy, a study was published 
and demonstrated an association of pre-treatment serum ALP levels and 
prognosis, albeit in a small group of patients (Thorpe et al., 1979).More 
recently studies with larger patient samples established the prognostic value 
of pre-treatment serum ALP.  It is reported that pre-treatment ALP levels to 
have a predictive value for survival, but not for chemotherapy response (Bacci 
et al., 1993; Ferrari et al., 2001; Stokkel et al., 2002). However, none of these 
studies however looked at the ALP levels after chemotherapy and before 
surgery. 
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There was a report in 2005 that evaluated on both the pre-treatment 
and post-treatment serum ALP; of which the authors concluded that ALP 
levels before chemotherapy, after chemotherapy, and the change of alkaline 
phosphatase after chemotherapy are possible valuable factors in predicting 
chemotherapy response and survival in high-grade osteosarcoma in adults 
(Bramer et al., 2005). 
 
In this study of 448 patients, the alkaline phosphatase levels were 
assessed before chemotherapy, after chemotherapy but before surgery, and 
the changes in the level of alkaline phosphatase after chemotherapy were 
recorded. For the analysis of the normalisation of serum ALP, patients were 
divided in 3 groups; firstly, those where pre- treatment serum ALP did 
normalise; secondly, where it did not; and lastly those where pre-treatment 
serum ALP levels at diagnosis was not raised were called not applicable, 
because obviously in these patients ALP could not normalise. For clarification 
purposes they classified ALP as normal (if the value is less than 100% of its 
upper limit), high (if the value is in between 100% and 200% of its upper limit) 
or very high (if the value is more than 200% of the upper limit). 
 
Furthermore they evaluated pre-treatment serum ALP and its relation 
to survival outcome, and they found out that normal or high pre-treatment 
serum ALP is associated with better survival at 10 years (64% and 70% 
respectively) than very high pre-treatment serum ALP (37%), which was 
statistically significant. In regards to post-treatment serum ALP, it was 
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significantly correlated with survival rates of 68%, 39% and 25% in the 
normal, high and very high group respectively. 
 
They observed that a pre-treatment serum ALP above twice normal 
value correlated with a far worse survival. If the levels of serum ALP 
decreased after chemotherapy, but was still raised, survival was better, but 
still worse than those patients that had their serum ALP normalised. Also, they 
mentioned that a raised post-chemotherapy serum ALP predicts poor 
chemotherapy response. They conclude that serum ALP, measured before 
chemotherapy, after chemotherapy, and the change of serum ALP after 
chemotherapy are possible valuable factors in predicting chemotherapy 
response and survival in high-grade osteosarcoma. This method is cost-
effective and reproducible easily, together with other factors, play a role in 
improving individual prognostication. Finally they recommended that it should 
therefore be determined systematically in a prospective manner in order to 
further evaluate its usefulness. 
 
Of note, there was a report that illustrated an association between 
these 2 serological markers, the authors observed a correlation between pre-
treatment serum LDH and ALP at presentation of the disease; they noted that 
pre-treatment serum LDH was significantly higher in patients who also had 
increased levels of ALP (30.0%), in comparison with those patients with 
normal values of the serological marker (15.0%) (Bacci et al., 2004). They 
also mentioned that the 5-year disease-free survival rates for pre-treatment 
serum ALP was at 67.3% for patients with normal values and 37.7% for those 
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patients with high values, which was statistically significant on a univariate 
analysis. 
 
Another relevant report, a study of 255 osteosarcoma patients, they 
demonstrated by multivariate analysis that the disease-free survival correlated 
with initial baseline lower pre-treatment serum ALP levels (Meyers et al., 
1993). 
 
A study from the Rizzoli Institute, focusing on evaluation of the 
relationship between patient-related and treatment-related factors and 
prognosis was carried out in 300 osteosarcoma patients, demonstrated that 
the pre-treatment serum ALP was a statistically significant predictive of 
disease-free survival, a higher 8-year DFS of 63%, was found in patients with 
normal values, as compared to patients with high values with the DFS rate of 
55% (Ferrari et al., 2001). 
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Other Possible Prognostic Factors: 
2.5.3  Age 
 Age at diagnosis is a well known prognostic factor in many different 
malignancies; its significance for patients with osteosarcoma is however 
controversial. Osteosarcoma in younger children may have a different 
prognosis compared to those in preadolescent age group. The fact that their 
physical and physiological status is dissimilar from that of adolescents, the 
pathophysiology of osteosarcoma development in this group might be 
different from that in adolescents. However, data on the clinical features and 
survival rates among preadolescent patients have shown conflicting results; 
some reports suggest a poorer prognosis in the older age group of patients 
(French Bone Tumour Study Group 1988; Scranton et al., 1975; Winkler et al., 
1984), whereas other studies show no difference (Bacci et al., 2005; Cho et 
al., 2006; Rytting et al., 2000). 
  
Age was then identified as a possible parameter of prognostic 
significance. 
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2.5.4 Gender 
 Osteosarcoma is known to be more common in males than in females. 
Females tend to develop it at a slightly earlier age; this is possibly because 
they tend to have their growth spurts earlier in their childhood. 
 
In regards to the Western literature, according to the findings by the 
U.S. Cancer Statistics Working Group (2004), the incidence rates and 95% 
confidence intervals of childhood and adolescent steosarcoma are 5.0 (4.4–
5.8) per million persons per year for males and 5.1(4.4–5.8) per million for 
females. Having said that, the incidence of osteosarcoma has always been 
considered to be higher in males than in females (Dahlin et al., 1986; Gurney 
et al., 1975; Mascarenhas et al., 1998).  
 
And recently, according to the most up to date SEER (Surveillance 
Epidemiology and End Results) data in 2008, it was a rate of 5.4 per million 
persons per year in males vs. 4.0 per million in females (Linabery & Ross, 
2008).A similar observation was also found in a study performed by the 
Scandinavian Sarcoma Group which showed that gender was linked with the 
outcome. They noted that female osteosarcoma patients had fewer relapses 
and better survival rates than their male counterparts (Saeter et al., 1997). 
This finding was also replicated in an analysis of prognostic factors by the 
Chinese group (Min et al., 2013). 
 
To gain more insight in the prognostic role of age, we performed this 
retrospective study in our institute. 
